Physician profile
James N Elia
NPI 1316168479
$3,803.38
in general payments reported to CMS, 2019-2025
20 companies · $830 in 2025
The $830 reported for 2025 was more than what 95% of Emergency Medical Services providers received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $49.14 · 2021: $202 · 2022: $955 · 2023: $1,193 · 2024: $307 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $790.83 | 2022-2024 | Andexxa, Atacand, Tezspire |
| Janssen Pharmaceuticals, INC | $402.72 | 2019-2024 | Xarelto |
| Inari Medical, INC. | $296.33 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $286.35 | 2025 | Flowtriever |
| Abbott Laboratories | $276.02 | 2023-2025 | Mitraclip, Navitor, I-Stat |
| Boston Scientific Corporation | $242.32 | 2019-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $158.74 | 2019-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $154.67 | 2022 | |
| Abiomed | $152.34 | 2023 | Impella |
| Heartflow, INC. | $149.90 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2023 | |
| Novo Nordisk INC | $124.77 | 2022 | |
| Genzyme Corporation | $124.25 | 2022 | |
| La Jolla Pharmaceutical Company | $112.39 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $108.94 | 2021-2024 | |
| Allergan, INC. | $65.74 | 2019 | |
| Chiesi USA, INC. | $48.86 | 2025 | Cleviprex |
| Pfizer INC. | $35.52 | 2023 | |
| Gilead Sciences, INC. | $22.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Elia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.